UNSPSC 51143702: Acetaminophen/diphenhydramine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51143702 Acetaminophen/diphenhydramine is a Commodity code under which state and local governments procure over-the-counter pharmaceuticals and pain-relief products, though recent opportunities under this code show significant scope variance. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida, for example, recently sought naloxone and safe drug deactivation systems through an IFB (Solicitation IFB60459723LAS, due July 26, 2023), while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 to establish master contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities, including Oregon. The MMCAP procurement requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products certified under current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission also posted a Request for Information in April 2026 to explore direct-to-manufacturer prescription programs, though this remained in the exploratory phase rather than a formal competitive solicitation.

Recent activity concentrates in Florida, Minnesota, and Texas, with the MMCAP cooperative structure extending reach across multiple states. The Seminole County solicitation required 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, electronic bidding submission, and compliance with federal requirements including E-Verify and drug-free workplace certification. The MMCAP RFP (due March 26, 2026) evaluated proposals on price competitiveness (75 percent weight), fixed pricing (10 percent), EDI capability and administrative fee compliance (5 percent each), and administrative data format compliance (5 percent), with awarded vendors effective July 1, 2026, subject to a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation. Vendors must carry commercial general liability of $5 million per occurrence and professional liability of $2 million, and all products must have expiration dates at least one year from manufacture with a minimum six-month shelf life.